Gene therapy for rare brain diseases: 5-Year safety check begins
NCT ID NCT06614569
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 7 people who previously received a gene therapy called AXO-AAV-GM2 for Tay-Sachs or Sandhoff disease — rare, fatal genetic disorders that destroy nerve cells. Researchers will track them for up to 5 years to see if the treatment remains safe and whether it helps slow the disease's natural course. The focus is on long-term side effects and changes in development, movement, and thinking skills.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AXO-AAV-GM2 gene therapy
What this could lead to
If successful, this could show that a single gene therapy treatment can slow or stabilize the devastating progression of Tay-Sachs and Sandhoff diseases over several years.
What could go wrong
This is a very small, early-stage follow-up study with only 7 participants. It cannot prove the therapy works broadly, and there are risks like cancer or immune disorders that need long-term monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SANDHOFF DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UMass Chan Medical School
Worcester, Massachusetts, 01655, United States